Document text
Principal Investigator: Scott Dexter Boyd
Organization: STANFORD UNIVERSITY
Fiscal Year: 2022
Award: $440,000
Funding agency: National Cancer Institute
Primary immune deficiency disorders (PID) affect 1 in 2,000 individuals in the U.S., twice the prevalence of non-Hodgkin lymphoma. PID patients are at risk for severe COVID-19 and impaired responses to vaccination. Research into vaccine boosting in these individuals is clearly of importance for public health. Study of these patients, many of which have single-gene inborn causes for their phenotype, offers the valuable opportunity to correlate genotypes with immunological phenotypes in humans. Dr. Boyd will collaborate with Dr. Charlotte Cunningham-Rundles, a world expert in PID at the Mount Sinai School of Medicine in New York, to analyze the serological and B and T lymphocyte responses to vaccination and boosting using previously-collected plasma and peripheral blood mononuclear cells from a cohort of 142 PID patients whose disorders affect adaptive immune responses with a range of severity, and whose immunological phenotypes can include autoreactivity in addition to impaired protective immunity. The most common diagnosis in this cohort is Common Variable Immune Deficiency, (CVID). These patients generate suboptimal vaccine responses, but some can still mount specific antibody titers after vaccination. We will carry out an in-depth systemsimmunology characterization of serological responses and B cell and T cell populations in these patients, characterizing the frequencies, cellular phenotypes, B cell and T cell receptor sequences, and antigen epitopes targeted by antigen-specific B cells, using a panel of 14 different DNA-tagged SARS-CoV-2 variant antigen tetramers. Examination of T cell responses in the PID patients will include analysis of vaccine antigen-stimulated T cell frequencies and TCR sequences, and detailed flow cytometric immunophenotyping. These data will provide clinically relevant information about SARS-CoV-2 vaccination and boosting responses in PID patients to potentially contribute to clinical guidance as new Omicron variant-containing vaccine boosters are implemented, and should provide insights into the immunological genes, pathways and cell populations that contribute to adaptive immune responses and memory formation after mRNA vaccination in human patients.
Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV variant><2019-nCoV variant forms><2019-nCoV variant strains><Acquired Agammaglobulinemia><Acute><Address><Affect><African American group><African American individual><African American people><African American population><African Americans><Agonist><Antibodies><Antibody titer measurement><Antigen Targeting><Antigenic Determinants><Antigens><Attention><Award><B blood cells><B cell><B cells><B-Cells><B-Lymphocytes><B-cell><Binding Determinants><Biopsy><Blood><Blood Plasma><Blood Plasma Cell><Blood Reticuloendothelial System><COVID infected patient><COVID patient><COVID positive patient><COVID-19><COVID-19 diagnosis><COVID-19 immune response><COVID-19 immunity><COVID-19 infected patient><COVID-19 infection><COVID-19 patient><COVID-19 positive patient><COVID-19 test><COVID-19 tests><COVID-19 vaccination><COVID-19 variant><COVID-19 variant forms><COVID-19 variant strains><COVID-19 virus><COVID19><COVID19 diagnosis><COVID19 immune response><COVID19 immunity><COVID19 infection><COVID19 patient><COVID19 positive patient><COVID19 test><COVID19 tests><COVID19 vaccination><COVID19 virus><CV-19><CV19><Cancer Patient><Caucasian><Caucasian Race><Caucasians><Caucasoid><Caucasoid Race><Cell Body><Cells><Clinical><Clinical Evaluation><Clinical Testing><CoV-2><CoV2><Collaborations><Common Variable Immunodeficiency><Communities><Convalescence><DNA><Data><Data Set><Dataset><Deoxyribonucleic Acid><Diagnosis><Disease><Disorder><Elderly><Epitopes><Evaluation><Female><Frequencies><Genes><Genotype><Hispanic Americans><Human><Immune><Immune memory><Immune response><Immune system><Immunes><Immunity><Immunochemical Immunologic><Immunodeficiency Disorder><Immunodeficiency Syndrome><Immunologic><Immunologic Deficiency Syndromes><Immunologic Memory><Immunologic Subtyping><Immunological><Immunological Deficiency Syndromes><Immunological Memory><Immunological response><Immunologically><Immunologics><Immunophenotyping><Impairment><Individual><Infection><Institution><Knowledge><Laboratories><Longitudinal Studies><MHC Receptor><Major Histocompatibility Complex Receptor><Modern Man><Mucosa><Mucosal Immune Responses><Mucosal Tissue><Mucous Membrane><Nasal><Nasal Passages Nose><New York><Non-Hodgkin's Lymphoma><Nonhodgkins Lymphoma><Nose><Occidental><PBMC><Pathway interactions><Patient Recruitments><Patients><Peripheral Blood Mononuclear Cell><Phenotype><Physicians><Plasma><Plasma Cells><Plasma Serum><Plasmacytes><Population><Populations at Risk><Prevalence><Primary Immunodeficiency><Prognosis><Protocol><Protocols documentation><Public Health><RNA immunization><RNA vaccination><Research><Respiratory System, Nose, Nasal Passages><Reticuloendothelial System, Serum, Plasma><Risk><Route><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV-2 diagnosis><SARS-CoV-2 immune response><SARS-CoV-2 immunity><SARS-CoV-2 infected patient><SARS-CoV-2 infection><SARS-CoV-2 patient><SARS-CoV-2 positive patient><SARS-CoV-2 test><SARS-CoV-2 tests><SARS-CoV-2 vaccination><SARS-CoV-2 variant><SARS-CoV-2 variant forms><SARS-CoV-2 variant strains><SARS-CoV2><SARS-CoV2 infection><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Science><Serology><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 immune response><Severe acute respiratory syndrome coronavirus 2 immunity><Severe acute respiratory syndrome coronavirus 2 infection><Severe acute respiratory syndrome coronavirus 2 vaccination><Severe acute respiratory syndrome related corona virus 2><Severities><Severity of illness><Site><T cell response><T-Cell Antigen Receptors><T-Cell Receptor><T-Cells><T-Lymphocyte><TLR protein><Testing><Tissue Sample><Toll-Like Receptor Family Gene><Toll-like receptors><Translational Research><Translational Science><Translations><Vaccination><Vaccine Antigen><Vaccines><Validation><Variant><Variation><Viral Antigens><Wuhan coronavirus><adaptive immune response><adaptive immunity><adult youth><advanced age><allergic/immunologic body system><allergic/immunologic organ system><anamnestic reaction><antibody titering><autoreactivity><booster dose><booster shot><booster vaccine><check point blockade><checkpoint blockade><clinical development><clinical relevance><clinical test><clinically relevant><cohort><common variable immune deficiency><common variable immuno-deficiency><congenital immunodeficiency><corona virus disease 2019><coronavirus disease 2019><coronavirus disease 2019 diagnosis><coronavirus disease 2019 immune response><coronavirus disease 2019 immunity><coronavirus disease 2019 infected patient><coronavirus disease 2019 infection><coronavirus disease 2019 patient><coronavirus disease 2019 positive patient><coronavirus disease 2019 test><coronavirus disease 2019 tests><coronavirus disease 2019 vaccination><coronavirus disease 2019 variant><coronavirus disease 2019 variant forms><coronavirus disease 2019 variant strains><coronavirus disease 2019 virus><coronavirus disease infected patient><coronavirus disease patient><coronavirus disease positive patient><coronavirus disease-19><coronavirus disease-19 patient><coronavirus disease-19 virus><coronavirus infectious disease-19><coronavirus of pandemic concern><coronavirus of pandemic potential><coronavirus patient><coronavirus with pandemic potential><data sharing><diagnosed with COVID-19><diagnosed with COVID19><diagnosed with SARS-CoV-2><diagnosed with coronavirus 2019><diagnosed with coronavirus disease 2019><disease severity><elders><geriatric><hCoV19><host response><hypoimmunity><immune check point blockade><immune checkpoint blockade><immune deficiency disorder><immune system response><immunity against COVID-19><immunity against COVID19><immunity against SARS-CoV-2><immunity against Severe acute respiratory syndrome coronavirus 2><immunity against coronavirus disease 2019><immunity to COVID-19><immunity to COVID19><immunity to SARS-CoV-2><immunity to Severe acute respiratory syndrome coronavirus 2><immunity to coronavirus disease 2019><immunodeficiency><immunogen><immunophenotype><immunoresponse><infected with COVID-19><infected with COVID19><infected with SARS-CoV-2><infected with SARS-CoV2><infected with coronavirus disease 2019><infected with severe acute respiratory syndrome coronavirus 2><insight><interest><late life><later life><life-threatening COVID><life-threatening COVID-19><life-threatening SARS-CoV-2><life-threatening coronavirus disease><life-threatening coronavirus disease 2019><life-threatening severe acute respiratory syndrome coronavirus 2><long-term study><longitudinal outcome studies><longterm study><mRNA immunization><mRNA vaccination><male><medical college><medical schools><medically disadvantaged><medically disadvantaged population><medically under served><medically under served group><medically under served population><medically underserved><medically underserved group><medically underserved population><member><nCoV2><new therapeutic approach><new therapeutic intervention><new therapeutic strategies><new therapy approaches><non-Hodgkins disease><novel therapeutic approach><novel therapeutic intervention><novel therapeutic strategies><novel therapy approach><older adult><older person><pandemic><pandemic coronavirus><pandemic disease><pandemic threat coronavirus><participant recruitment><pathway><patient infected with COVID><patient infected with COVID-19><patient infected with SARS-CoV-2><patient infected with coronavirus disease><patient infected with coronavirus disease 2019><patient infected with severe acute respiratory syndrome coronavirus 2><patient population><patient with COVID><patient with COVID-19><patient with COVID19><patient with SARS-CoV-2><patient with coronavirus disease><patient with coronavirus disease 2019><patient with severe acute respiratory distress syndrome coronavirus 2><plasmocyte><primary immune deficiency><research clinical testing><response><school of medicine><secondary immune response><senior citizen><serious COVID><serious COVID-19><serious SARS-CoV-2><serious coronavirus disease><serious coronavirus disease 2019><serious severe acute respiratory syndrome coronavirus 2><severe COVID><severe COVID-19><severe COVID19><severe SARS-CoV-2><severe acute respiratory syndrome coronavirus 2 diagnosis><severe acute respiratory syndrome coronavirus 2 infected patient><severe acute respiratory syndrome coronavirus 2 patient><severe acute respiratory syndrome coronavirus 2 positive patient><severe acute respiratory syndrome coronavirus 2 test><severe acute respiratory syndrome coronavirus 2 tests><severe acute respiratory syndrome coronavirus 2 variant><severe acute respiratory syndrome coronavirus 2 variant forms><severe acute respiratory syndrome coronavirus 2 variant strains><severe coronavirus disease><severe coronavirus disease 19><severe coronavirus disease 2019><severe severe acute respiratory syndrome coronavirus 2><thymus derived lymphocyte><tool><translation research><vaccinate against COVID-19><vaccinate against COVID19><vaccinate against SARS-CoV-2><vaccinate against coronavirus disease 2019><vaccinate against severe acute respiratory syndrome coronavirus 2><vaccination against COVID-19><vaccination against COVID19><vaccination against SARS-CoV-2><vaccination against Severe acute respiratory syndrome coronavirus 2><vaccination against coronavirus disease 2019><vaccine candidate><vaccine response><vaccine responsiveness><vaccine-induced response><virus antigen><white race><young adult><young adulthood>